← Back to Aarti Pharmalabs Ltd Overview
📊Financials📈PE Ratio🥧Shareholding💰Dividend📋Quarterly⚖️Balance Sheet💹P&L🌊Cash Flow
AARTIPHARMPharmaceuticals

Aarti Pharmalabs Ltd — Profit & Loss Statement

₹591.95
-4.72%

Aarti Pharmalabs Ltd Profit & Loss Statement (Annual)

Metric20252024202320222021
Tax Effect Of Unusual Items0.000.000.02 Cr29423.55—
Tax Rate For Calcs0.240.280.260.21—
Normalized EBITDA474.49 Cr390.94 Cr344.29 Cr197.83 Cr—
EBITDA474.49 Cr390.94 Cr344.37 Cr197.84 Cr—
Net Income From Continuing Operation Net Minority Interest272.40 Cr216.90 Cr193.49 Cr122.25 Cr—
Reconciled Depreciation86.90 Cr73.24 Cr62.54 Cr42.12 Cr—
Reconciled Cost Of Revenue1.13K Cr1.02K Cr1.25K Cr879.70 Cr—
EBIT387.59 Cr317.71 Cr281.83 Cr155.72 Cr—
Net Interest Income-26.90 Cr-17.21 Cr-20.11 Cr-11.95 Cr—
Interest Expense26.90 Cr17.21 Cr21.05 Cr0.34 Cr—
Normalized Income272.40 Cr216.90 Cr193.43 Cr122.24 Cr—
Net Income From Continuing And Discontinued Operation272.40 Cr216.90 Cr193.49 Cr122.25 Cr—
Total Expenses1.74K Cr1.54K Cr1.66K Cr1.03K Cr—
Diluted Average Shares9.07 Cr9.06 Cr9.06 Cr9.06 Cr—
Basic Average Shares9.06 Cr9.06 Cr9.06 Cr9.06 Cr—
Diluted EPS30.0423.9321.3513.49—
Basic EPS30.0623.9321.3513.49—
Diluted NI Availto Com Stockholders272.40 Cr216.90 Cr193.49 Cr122.25 Cr—
Net Income Common Stockholders272.40 Cr216.90 Cr193.49 Cr122.25 Cr—
Otherunder Preferred Stock Dividend0.000.000.000.00—
Net Income272.40 Cr216.90 Cr193.49 Cr122.25 Cr—
Net Income Including Noncontrolling Interests272.40 Cr216.90 Cr193.49 Cr122.25 Cr—
Net Income Continuous Operations272.40 Cr216.90 Cr193.49 Cr122.25 Cr—
Tax Provision88.28 Cr83.59 Cr67.28 Cr33.13 Cr—
Pretax Income360.69 Cr300.49 Cr260.77 Cr155.38 Cr—
Other Non Operating Income Expenses10.12 Cr4.89 Cr0.05 Cr-0.32 Cr—
Net Non Operating Interest Income Expense-26.90 Cr-17.21 Cr-20.11 Cr-11.95 Cr—
Interest Expense Non Operating26.90 Cr17.21 Cr21.05 Cr0.34 Cr—
Operating Income377.47 Cr312.81 Cr279.51 Cr165.16 Cr—
Operating Expense609.73 Cr519.08 Cr402.53 Cr147.17 Cr—
Other Operating Expenses360.87 Cr307.44 Cr81.38 Cr0.06 Cr—
Depreciation And Amortization In Income Statement86.90 Cr73.24 Cr62.54 Cr42.12 Cr—
Depreciation Income Statement86.90 Cr73.24 Cr62.50 Cr42.12 Cr—
Gross Profit987.20 Cr831.89 Cr682.04 Cr312.33 Cr—
Cost Of Revenue1.13K Cr1.02K Cr1.25K Cr879.70 Cr—
Total Revenue2.12K Cr1.85K Cr1.94K Cr1.19K Cr—
Operating Revenue2.12K Cr1.85K Cr1.94K Cr1.19K Cr—
Total Unusual Items—1.22 Cr0.08 Cr0.01 Cr0.00
Total Unusual Items Excluding Goodwill—1.22 Cr0.08 Cr0.01 Cr0.00
Interest Income—3.04 Cr0.94 Cr57000.000.00
Rent Expense Supplemental—1.16 Cr4.00 Cr0.12 Cr0.00
Special Income Charges—0.02 Cr-0.06 Cr0.01 Cr0.00
Other Special Charges—-0.02 Cr0.06 Cr-0.02 Cr—
Interest Income Non Operating—3.04 Cr0.94 Cr57000.000.00
Amortization—1.27 Cr0.04 Cr——
Research And Development—8.37 Cr13.96 Cr——
Selling General And Administration—80.36 Cr88.19 Cr27.64 Cr46000.00
Selling And Marketing Expense—67.97 Cr73.75 Cr26.14 Cr0.00
General And Administrative Expense—12.39 Cr14.44 Cr1.51 Cr46000.00
Rent And Landing Fees—1.16 Cr4.00 Cr0.12 Cr0.00
Minority Interests——0.00——
Write Off——59000.0070000.000.00
Total Other Finance Cost——1.42 Cr11.62 Cr—

All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.

More on Aarti Pharmalabs Ltd

OverviewFinancialsPE HistoryShareholdingQuarterlyBalance SheetP&LCash FlowPharmaceuticals StocksScreener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.